Brief: Sangamo Therapeutics & Astellas Enter Capsid License Agreement

Sangamo Therapeutics

19/12/2024 07:35

Dec 19 (Reuters) - Sangamo Therapeutics Inc  SGMO.O  &
Astellas Pharma Inc  4503.T :
    * SANGAMO THERAPEUTICS AND ASTELLAS ANNOUNCE CAPSID LICENSE
AGREEMENT TO DELIVER GENOMIC MEDICINES FOR NEUROLOGICAL DISEASES
    * SANGAMO THERAPEUTICS INC - ELIGIBLE FOR UP TO $1.3 BILLION
IN
MILESTONE PAYMENTS
    * SANGAMO THERAPEUTICS INC - TO RECEIVE $20 MILLION UPFRONT
LICENSE FEE

Source text:  ID:nBw8WQ71Ra 
Further company coverage:  4503.T 

 ((Reuters.Briefs@thomsonreuters.com))